With the current lack of evidence-based guidelines, the answer requires a detailed risks-versus-benefits conversation with your healthcare provider
Starting with Glpcare ensures you get that continuous connection to health professionals
Taken together, the evidence supports using racemic ALA which is why it forms the basis of our top recommendation
And in the U.S., that grid upgrade, to be blunt, has lagged some of the rest of the world
Glutathione also has non-antioxidant related protective and detoxification benefits
To put that into more concrete terms: on the 0 to 18 CDR-SB scale, lecanemab, a monoclonal antibody thats not approved on the NHS (because of cost) but is approved by the FDA, showed a 0.45-point advantage at 18 months, which is about 27% slower than placebo